A First-in-human Clinical Evaluation of the Novel Intravenous Contrast Agent SN132D in Patients With Breast and Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2023 According to a Spago NanoMedical media release, company worked on producing the final report for the completed SPAGOPIX-01 study in which the MRI contrast agent SN132D was evaluated in breast cancer at start of 2023.
09 May 2023 According to a Spago NanoMedical media release, Intensive work is now underway to complete the final report from this study and company expect to be able to present full results from the study later this year.
07 Dec 2022 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com